229 related articles for article (PubMed ID: 34637549)
1. Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.
Gauhar A; Privezentzev CV; Demydchuk M; Gerlza T; Rieger J; Kungl AJ; Walsh FS; Rutkowski JL; Stocki P
FASEB J; 2021 Nov; 35(11):e21970. PubMed ID: 34637549
[TBL] [Abstract][Full Text] [Related]
2. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD.
Liu X; Wang Y; Sun L; Xiao G; Hou N; Chen J; Wang W; Xu X; Gu Y
Antiviral Res; 2024 Jun; 226():105898. PubMed ID: 38692413
[TBL] [Abstract][Full Text] [Related]
3. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
4. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124
[TBL] [Abstract][Full Text] [Related]
6. Identification of nurse shark V
Buffington J; Duan Z; Kwon HJ; Hong J; Li D; Feng M; Xie H; Ho M
FASEB J; 2023 Jun; 37(6):e22973. PubMed ID: 37191949
[TBL] [Abstract][Full Text] [Related]
7. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
8. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography.
Ubah OC; Lake EW; Gunaratne GS; Gallant JP; Fernie M; Robertson AJ; Marchant JS; Bold TD; Langlois RA; Matchett WE; Thiede JM; Shi K; Yin L; Moeller NH; Banerjee S; Ferguson L; Kovaleva M; Porter AJ; Aihara H; LeBeau AM; Barelle CJ
Nat Commun; 2021 Dec; 12(1):7325. PubMed ID: 34916516
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.
Kim YJ; Lee MH; Lee SR; Chung HY; Kim K; Lee TG; Kim DY
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671877
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
[TBL] [Abstract][Full Text] [Related]
12. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.
Liu Y; Soh WT; Kishikawa JI; Hirose M; Nakayama EE; Li S; Sasai M; Suzuki T; Tada A; Arakawa A; Matsuoka S; Akamatsu K; Matsuda M; Ono C; Torii S; Kishida K; Jin H; Nakai W; Arase N; Nakagawa A; Matsumoto M; Nakazaki Y; Shindo Y; Kohyama M; Tomii K; Ohmura K; Ohshima S; Okamoto T; Yamamoto M; Nakagami H; Matsuura Y; Nakagawa A; Kato T; Okada M; Standley DM; Shioda T; Arase H
Cell; 2021 Jun; 184(13):3452-3466.e18. PubMed ID: 34139176
[TBL] [Abstract][Full Text] [Related]
13. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
Nat Commun; 2020 Sep; 11(1):4528. PubMed ID: 32913273
[TBL] [Abstract][Full Text] [Related]
14. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
[TBL] [Abstract][Full Text] [Related]
15. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
Noy-Porat T; Makdasi E; Alcalay R; Mechaly A; Levy Y; Bercovich-Kinori A; Zauberman A; Tamir H; Yahalom-Ronen Y; Israeli M; Epstein E; Achdout H; Melamed S; Chitlaru T; Weiss S; Peretz E; Rosen O; Paran N; Yitzhaki S; Shapira SC; Israely T; Mazor O; Rosenfeld R
Nat Commun; 2020 Aug; 11(1):4303. PubMed ID: 32855401
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
17. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition.
Hattori T; Koide A; Noval MG; Panchenko T; Romero LA; Teng KW; Tada T; Landau NR; Stapleford KA; Koide S
J Mol Biol; 2021 Feb; 433(3):166748. PubMed ID: 33310017
[TBL] [Abstract][Full Text] [Related]
18. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
[TBL] [Abstract][Full Text] [Related]
19. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
20. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
